AGER and Parkinson disease: Moreover, vildagliptin, a DPP-4 inhibitor, blocked the receptor for advanced glycation end products (RAGE) activated-NF-κB pro-inflammatory signaling cascade, prevented dopaminergic neuron death, and ameliorated motor impairment in the rat rotenone model of PD [147].